Bausch + Lomb (BLCO) net assets (shareholders' equity)

Net assets · fiscal 2025
$6.45B

Bausch + Lomb (BLCO) had net assets of $6.45B at the end of fiscal 2025 (December 31, 2025). That is 0.4% lower than the $6.47B of fiscal 2024. Figures as of 19 Nov 2026, 11:21 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Net assets, fiscal 2025
$6.45B
Change on fiscal 2024
−0.4%
Growth, 5 years
−8.4% a year
Highest on record
$9.99Bfiscal 2020
Lowest on record
$6.45Bfiscal 2025
Fiscal years on record
62020–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.

Bausch + Lomb net assets (shareholders' equity), in more detail

Over the five fiscal years to 2025 net assets shrank at a compound 8.4% a year. Across the 6 fiscal years on record (2020–2025), the highest was $9.99B in fiscal 2020 and the lowest $6.45B in fiscal 2025.

History · 6 fiscal years

Net assets by fiscal year

Bausch + Lomb net assets (shareholders' equity), year by year

Bausch + Lomb (BLCO) net assets (shareholders' equity) by fiscal year
Fiscal yearNet assetsChangeYear ended
2025$6.45B 0.4% down
2024$6.47B 5.5% down
2023$6.85B 2.6% down
2022$7.03B 24.6% down
2021$9.33B 6.6% down
2020$9.99B—

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Net assets is shareholders' equity on the balance sheet at the fiscal year-end: total assets minus total liabilities, also called book value.

How to read it

Large buybacks and write-offs shrink it without the business getting worse, so a falling or negative figure needs the reason before a verdict.

Net assets at health care companies of similar size

Net assets of Bausch + Lomb and comparable companies
CompanyNet assetsFiscal year
ImmunityBio IBRX-$500.47M2025
Cytokinetics CYTK-$659.63M2025
ABIVAX ABVX€455.21M2025
Bausch + Lomb BLCO$6.45B2025
Amneal Pharmaceuticals AMRX-$70.79M2025
Caris Life Sciences CAI$577.31M2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on BLCO

Bausch + Lomb, figure by figure

Bausch + Lomb (BLCO) overview: price, valuation and scorecardAll health care companies by market value

Bausch + Lomb net assets (shareholders' equity): questions and answers

What are Bausch + Lomb's net assets?

Bausch + Lomb (BLCO) had net assets of $6.45B at the end of fiscal 2025 (December 31, 2025). That is 0.4% lower than the $6.47B of fiscal 2024.

What is the growth rate of Bausch + Lomb's net assets?

Over the five fiscal years to 2025 net assets shrank at a compound 8.4% a year.

What are the highest and lowest net assets figures on record for Bausch + Lomb?

Across the 6 fiscal years on record (2020–2025), the highest was $9.99B in fiscal 2020 and the lowest $6.45B in fiscal 2025.

How is Bausch + Lomb's net assets calculated?

Net assets is shareholders' equity on the balance sheet at the fiscal year-end: total assets minus total liabilities, also called book value. For Bausch + Lomb it is on record here for 6 fiscal years, 2020 to 2025.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Bausch + Lomb (BLCO) net assets (shareholders' equity)”, data as of 19 November 2026. https://funkfolio.com/stock/BLCO/net-assets

Underlying data: the company's filings with the SEC and Yahoo Finance.